Previous 10 | Next 10 |
Salarius Pharmaceuticals press release ( NASDAQ: SLRX ): Q2 GAAP EPS of -$0.09 beats by $0.01 . Cash and equivalents were $22.6 million as of June 30, 2022, compared with $29.2 million as of December 31, 2021 Shares -9% PM. For further details see: Sa...
HOUSTON, Aug. 08, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX) , a clinical-stage biopharmaceutical company developing cancer therapies for patients in need of new treatment options, today reported financial results for the three and six months ended Ju...
SLRX For Seeking Alpha's full earnings season calendar, click here . For further details see: Notable earnings after Friday's close
HOUSTON, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX) , a clinical-stage biopharmaceutical company developing therapies for patients with cancer in need of new treatment options, announces the addition of four prestigious institutions to the open-label...
Clinical-stage biopharmaceutical firm Salarius Pharmaceuticals ( NASDAQ: SLRX ) and VolitionRx ( NYSE: VNRX ), a developer of blood tests, have signed a research and development agreement, the companies said on Tuesday. Salarius ( SLRX ) stock jumped...
HOUSTON, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX) , a clinical-stage biopharmaceutical company developing therapies for patients with cancer in need of new treatment options, and VolitionRx Limited (NYSE American: VNRX) , a multinational epigen...
HOUSTON, July 29, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX) , a clinical-stage biopharmaceutical company developing cancer therapies for patients in need of new treatment options, today announced that the Company will report its second quarter 2022 f...
Salarius Pharmaceuticals (NASDAQ:SLRX) on Friday filed for resale of up to ~7M shares by selling stockholders, issuable on exercise of certain outstanding warrants. The warrants were issued to the selling stockholders in a private placement concurrent with a registered direct offering of...
HOUSTON, Texas, June 09, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX), a clinical-stage biopharmaceutical company developing cancer therapies for patients in need of new treatment options, today announced that the Company will participate in the 2022 BIO Internation...
HOUSTON, May 18, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with sarcomas, pediatric cancers, and other solid and hematological cancers, today announced that David Art...
News, Short Squeeze, Breakout and More Instantly...
Salarius Pharmaceuticals Inc. Company Name:
SLRX Stock Symbol:
NYSE Market:
Salarius Pharmaceuticals Inc. Website:
2024-06-17 09:02:04 ET Solar Acquisition Corp (SLRX) announced stock split at a ratio of 1-for-8 on 2024-06-17 ... Full story available on KlickAnalytics.com
Patients were treated in the dose-escalation portion of the Phase 1/2 study evaluating seclidemstat in combination with azacitidine Investigators reported a 43% overall response rate among 14 predominantly higher risk myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (C...
HOUSTON, June 12, 2024 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX) , a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for patients in need of new treatment options, today announced that it will effect...